Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyBucindolol
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Bucindolol
- Accession Number
- DB12752
- Type
- Small Molecule
- Groups
- Investigational
- Description
Bucindolol has been investigated in Heart Failure.
- Structure
Structure for Bucindolol (DB12752)
- Synonyms
- Not Available
- Categories
- Adrenergic Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Adrenergic beta-Antagonists
- Agents causing hyperkalemia
- Alcohols
- Amines
- Amino Alcohols
- Autonomic Agents
- Bradycardia-Causing Agents
- Cardiovascular Agents
- Cytochrome P-450 CYP2D6 Substrates
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Propanols
- Sympathomimetics
- Vasodilating Agents
- UNII
- E9UO06K7CE
- CAS number
- 71119-11-4
- Weight
- Average: 363.461
Monoisotopic: 363.194677057 - Chemical Formula
- C22H25N3O2
- InChI Key
- FBMYKMYQHCBIGU-UHFFFAOYSA-N
- InChI
- InChI=1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3
- IUPAC Name
- 2-(2-hydroxy-3-{[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino}propoxy)benzonitrile
- SMILES
- CC(C)(CC1=CNC2=CC=CC=C12)NCC(O)COC1=CC=CC=C1C#N
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (4R)-limonene (4R)-limonene may decrease the antihypertensive activities of Bucindolol. 1,10-Phenanthroline 1,10-Phenanthroline may increase the bradycardic activities of Bucindolol. 4-Methoxyamphetamine 4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Acebutolol Acebutolol may increase the orthostatic hypotensive activities of Bucindolol. Aceclofenac Aceclofenac may decrease the antihypertensive activities of Bucindolol. Acemetacin Acemetacin may decrease the antihypertensive activities of Bucindolol. Acepromazine Bucindolol may increase the antihypertensive activities of Acepromazine. Aceprometazine Aceprometazine may increase the hypotensive activities of Bucindolol. Acetohexamide Bucindolol may increase the hypoglycemic activities of Acetohexamide. Acetylcholine The risk or severity of adverse effects can be increased when Bucindolol is combined with Acetylcholine. - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Compound
- 51045
- PubChem Substance
- 347828941
- ChemSpider
- 46266
- BindingDB
- 50169808
- ChEMBL
- CHEMBL321582
- PharmGKB
- PA165945764
- Wikipedia
- Bucindolol
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Current or Recent History of Atrial Fibrillation 1 Not Available Unknown Status Not Available Heart Failure, Unspecified 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00744 mg/mL ALOGPS logP 3.4 ALOGPS logP 3.49 ChemAxon logS -4.7 ALOGPS pKa (Strongest Acidic) 14.09 ChemAxon pKa (Strongest Basic) 9.69 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 81.07 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 106.44 m3·mol-1 ChemAxon Polarizability 39.98 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- Sub Class
- Indoles
- Direct Parent
- 3-alkylindoles
- Alternative Parents
- Phenoxy compounds / Phenol ethers / Benzonitriles / Aralkylamines / Alkyl aryl ethers / Substituted pyrroles / Heteroaromatic compounds / Secondary alcohols / 1,2-aminoalcohols / Nitriles show 4 more
- Substituents
- 3-alkylindole / Phenoxy compound / Benzonitrile / Phenol ether / Alkyl aryl ether / Aralkylamine / Monocyclic benzene moiety / Benzenoid / Substituted pyrrole / Heteroaromatic compound show 18 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 . [PubMed:17125412]
- Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961]
- Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2. [PubMed:27836712]
Drug created on October 20, 2016 18:01 / Updated on October 01, 2018 15:20